These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11591503)

  • 1. Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists.
    Barrow JC; Nantermet PG; Selnick HG; Glass KL; Ngo PL; Young MB; Pellicore JM; Breslin MJ; Hutchinson JH; Freidinger RM; Condra C; Karczewski J; Bednar RA; Gaul SL; Stern A; Gould R; Connolly TM
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2691-6. PubMed ID: 11591503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1).
    Nantermet PG; Barrow JC; Lundell GF; Pellicore JM; Rittle KE; Young M; Freidinger RM; Connolly TM; Condra C; Karczewski J; Bednar RA; Gaul SL; Gould RJ; Prendergast K; Selnick HG
    Bioorg Med Chem Lett; 2002 Feb; 12(3):319-23. PubMed ID: 11814787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-peptidic small-molecule antagonists of the human platelet thrombin receptor PAR-1.
    Selnick HG; Barrow JC; Nantermet PG; Connolly TM
    Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):47-59. PubMed ID: 15317290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
    Wu CC; Teng CM
    Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.
    Derian CK; Damiano BP; Addo MF; Darrow AL; D'Andrea MR; Nedelman M; Zhang HC; Maryanoff BE; Andrade-Gordon P
    J Pharmacol Exp Ther; 2003 Feb; 304(2):855-61. PubMed ID: 12538843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.
    Zhang HC; Derian CK; Andrade-Gordon P; Hoekstra WJ; McComsey DF; White KB; Poulter BL; Addo MF; Cheung WM; Damiano BP; Oksenberg D; Reynolds EE; Pandey A; Scarborough RM; Maryanoff BE
    J Med Chem; 2001 Mar; 44(7):1021-4. PubMed ID: 11297447
    [No Abstract]   [Full Text] [Related]  

  • 7. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.
    Andrade-Gordon P; Derian CK; Maryanoff BE; Zhang HC; Addo MF; Cheung Wm ; Damiano BP; D'Andrea MR; Darrow AL; de Garavilla L; Eckardt AJ; Giardino EC; Haertlein BJ; McComsey DF
    J Pharmacol Exp Ther; 2001 Jul; 298(1):34-42. PubMed ID: 11408522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist.
    Ahn HS; Foster C; Boykow G; Stamford A; Manna M; Graziano M
    Biochem Pharmacol; 2000 Nov; 60(10):1425-34. PubMed ID: 11020444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif.
    Hoekstra WJ; Hulshizer BL; McComsey DF; Andrade-Gordon P; Kauffman JA; Addo MF; Oksenberg D; Scarborough RM; Maryanoff BE
    Bioorg Med Chem Lett; 1998 Jul; 8(13):1649-54. PubMed ID: 9873407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
    Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
    Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin receptor antagonists; recent advances in PAR-1 antagonist development.
    Anderluh M; Dolenc MS
    Curr Med Chem; 2002 Jul; 9(13):1229-50. PubMed ID: 12052165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists.
    Ahn HS; Arik L; Boykow G; Burnett DA; Caplen MA; Czarniecki M; Domalski MS; Foster C; Manna M; Stamford AW; Wu Y
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2073-8. PubMed ID: 10450984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
    Kahn ML; Nakanishi-Matsui M; Shapiro MJ; Ishihara H; Coughlin SR
    J Clin Invest; 1999 Mar; 103(6):879-87. PubMed ID: 10079109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1).
    McComsey DF; Hawkins MJ; Andrade-Gordon P; Addo MF; Oksenberg D; Maryanoff BE
    Bioorg Med Chem Lett; 1999 May; 9(10):1423-8. PubMed ID: 10360749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.
    Chackalamannil S
    Curr Top Med Chem; 2003; 3(10):1115-23. PubMed ID: 12769712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of proteinase-activated receptor agonists on human platelets.
    Chung AW; Jurasz P; Hollenberg MD; Radomski MW
    Br J Pharmacol; 2002 Mar; 135(5):1123-32. PubMed ID: 11877318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin.
    Ofosu FA
    Transfus Apher Sci; 2003 Jun; 28(3):265-8. PubMed ID: 12725953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand.
    Moschonas IC; Kellici TF; Mavromoustakos T; Stathopoulos P; Tsikaris V; Magafa V; Tzakos AG; Tselepis AD
    Platelets; 2017 Dec; 28(8):812-821. PubMed ID: 28267389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of thrombin and SFLLR-peptide stimulation of platelet aggregation, phospholipase A2 and Na+/H+ exchange by a thrombin receptor antagonist.
    Seiler SM; Peluso M; Michel IM; Goldenberg H; Fenton JW; Riexinger D; Natarajan S
    Biochem Pharmacol; 1995 Feb; 49(4):519-28. PubMed ID: 7872957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide.
    Zhang HC; McComsey DF; White KB; Addo MF; Andrade-Gordon P; Derian CK; Oksenberg D; Maryanoff BE
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2105-9. PubMed ID: 11514149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.